Mayo Gets FDA Approval for New Imaging Agent for Recurrent Prostate Cancer: Urology

Evaluating men for prostate cancer recurrence has long been a major challenge; physicians have had to wait until a patient’s prostate-specific antigen, or PSA, levels rose to values between 20-30 ng/mL to identify sites of recurrent prostate cancer. Mayo Clinic has received U.S. Food and Drug Administration approval to produce and administer Choline C 11 Injection, an imaging agent used during a positron emission tomography scan to help detect sites of recurrent prostate cancer. In contrast to conventional imaging technologies, PET imaging with Choline C 11 can help identify sites of recurrence for tissue sampling and examination when a patient’s PSA level reaches 2 ng/mL — months or years earlier than before and allows physicians to pinpoint the locations of recurrent cancer more accurately and develop more effective treatment strategies. About 90,000 men annually seek treatment for recurrent prostate cancer. Click here to see full prescribing information for Choline C 11 Injection.
Dr. Eugene Kwon, a Mayo Clinic Urologist explains more.


Leave a Reply

Your email address will not be published. Required fields are marked *